Ciphergen Biosystems, Inc.
This article was originally published in The Gray Sheet
Executive SummaryProposed initial public offering of up to $86.3 mil. in common stock would fund expanded sales and marketing capabilities, R&D and corporate facilities, according to a preliminary prospectus filed with the Securities and Exchange Commission. The Palo Alto, California-based firm's ProteinChip protein analysis tool enables protein discovery, characterization and assay development for the protein-based biology research market. The current Series PBS II ProteinChip system debuted in May 1999. Ciphergen has 60 employees and in 1999 recorded sales of $5 mil., up 70.8%. A net loss of $7.7 mil. for the year compares to a loss of $8.3 mil. in 1998. The IPO is being underwritten by SG Cowen, ING Barings and Warburg Dillon Read
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.